Pliant Therapeutics(US:PLRX)2025-11-06 21:09Financial Performance - Research and development expenses for Q3 2025 were $17.9 million, down from $47.8 million in Q3 2024, primarily due to the discontinuation of the BEACON-IPF trial[6] - General and administrative expenses decreased to $10.3 million in Q3 2025 from $14.3 million in Q3 2024, attributed to lower personnel-related costs from workforce restructuring[6] - The net loss for Q3 2025 was $26.3 million, a reduction from $57.8 million in the same quarter last year, mainly due to the discontinuation of BEACON-IPF and reduced personnel costs[6] - Total operating expenses for Q3 2025 were $28.3 million, significantly lower than $62.0 million in Q3 2024[11] Cash and Assets - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $243.3 million[6] - The total assets as of September 30, 2025, were $276.6 million, down from $396.9 million at the end of 2024[13] Clinical Trials - The Phase 1 trial of PLN-101095 in solid tumors has completed enrollment, with interim data showing a 50% objective response rate in one of the dose cohorts[3] - Close out activities for the BEACON-IPF Phase 2b/3 clinical trial are expected to be completed in Q4 2025, with full results to be submitted for future publication[4] Strategic Initiatives - The company is evaluating a range of opportunities to create shareholder value moving forward[3] - The company completed a voluntary prepayment of all outstanding principal and interest under the March 11, 2024 Loan Agreement with Oxford Finance LLC in October 2025[5]